Sermonix Pharmaceuticals Employee Directory
Pharmaceutical ManufacturingUnited States11-50 Employees
Sermonix Pharmaceuticals, founded by David Portman, MD—a leading clinical researcher and expert in women’s health—focuses on developing targeted therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers. Our ELAINE Studies are evaluating an investigational oral drug, lasofoxifene, a novel targeted endocrine agent, in women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer harboring an ESR1 mutation(s).